
Cellectis and Cytovia in US$760m licence deal
Cytovia Therapeutics, Inc. and French Cellectis SAS have struck a licence deal to combine their different expertises in allogenic cancer cell...

Media hype on Denmark’s decision to halt AZD1222 vaccination
Since Denmark suspended vaccination with AstraZeneca’s bashed Covid-19 vaccine, AZD1222 is facing questions over its safety. Denmark’s...

Servier and MiNA Therapeutics sign €220m deal
Under the agreement, MiNA Therapeutics will use its small activating RNA platform (saRNA) to identify candicate saRNAs that can restore normal cell...

Omnix Medical bags €10.8m from EIC Accerator Fund
The money for the trial comes from the EIC Accelerator, for which last year 38 companies with potential breakthrough innovations were selected to...

C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
The company's subsidiary C4X Discovery Ltd got €7m upfront with potential to gain €414m in total for the global commercialisation rights for its...

MaxiVAX and Minaris Regenerative Medicine ink contract
Under the contract, Minaris will be responsible for the GMP manufacturing, freezing and shipping of MVX-ONCO-2, a cell-based immunotherapy for the...

Oxular Ltd raises US$37m
Oxford-based Oxular said it will use the proceeds to finance Phase II studies evaluatingO the company’s lead asset, OXU-001, for the treatment of...